 |
|
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Yuanbin Liu, Mingkai Chen
Clin Mol Hepatol. 2023;29(1):163-164. Published online 2022 Oct 27 DOI: https://doi.org/10.3350/cmh.2022.0326
|
|
Citations to this article as recorded by
 Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
|